Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Minimal Change Disease (MCD)”

15 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 15 of 15 results

Testing effectiveness (Phase 2)Study completedNCT02592798
What this trial is testing

Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD)

Who this might be right for
Nephrotic SyndromeFocal Segmental GlomerulosclerosisMinimal Change Disease
Bristol-Myers Squibb 36
Testing effectiveness (Phase 2)Looking for participantsNCT06466135
What this trial is testing

Study of WAL0921 in Patients With Glomerular Kidney Diseases

Who this might be right for
Diabetic NephropathiesPrimary Focal Segmental GlomerulosclerosisMinimal Change Disease+2 more
Walden Biosciences 96
Not applicableStudy completedNCT01451710
What this trial is testing

The Effectiveness of Enough Steroids as Inducement Therapy in Minimal Change Disease-like IgA Nephropathy

Who this might be right for
IgA Nephropathy
Nanjing University School of Medicine 30
Large-scale testing (Phase 3)Study completedNCT00981838
What this trial is testing

Rituximab in Multirelapsing Minimal Change Disease (MCD) or Focal Segmental Glomerulosclerosis (FSGS)

Who this might be right for
Nephrotic Syndrome
Mario Negri Institute for Pharmacological Research 24
Not applicableLooking for participantsNCT03949972
What this trial is testing

The FOrMe Registry (The German Focal Segmental Glomerulosclerosis and Minimal Change Disease Registry)

Who this might be right for
Glomerulosclerosis, Focal SegmentalMinimal Change DiseaseIdiopathic Nephrotic Syndrome
Prof. Dr. Paul Brinkkoetter 500
Testing effectiveness (Phase 2)Ended earlyNCT05441826
What this trial is testing

Efficacy and Safety of VB119 in Subjects With Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS)

Who this might be right for
Minimal Change DiseaseFocal Segmental Glomerulosclerosis
Tenet Medicines 1
Testing effectiveness (Phase 2)Study completedNCT04009668
What this trial is testing

Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease

Who this might be right for
FSGSMCDFocal Segmental Glomerulosclerosis+1 more
University of Michigan 7
Not applicableLooking for participantsNCT04571658
What this trial is testing

NEPTUNE Match Study

Who this might be right for
Nephrotic Syndrome in ChildrenFocal Segmental GlomerulosclerosisMinimal Change Disease+6 more
University of Michigan 375
Not applicableLooking for participantsNCT01209000
What this trial is testing

Nephrotic Syndrome Study Network

Who this might be right for
Minimal Change Disease (MCD)Membranous NephropathyGlomerulosclerosis, Focal Segmental
University of Michigan 1,200
Large-scale testing (Phase 3)Not Yet RecruitingNCT06405100
What this trial is testing

Efficacy and Safety of Tacrolimus in Combination With Ripertamab in the Initial Treatment of Patients With MCD

Who this might be right for
Minimal Change Disease
Air Force Military Medical University, China 81
Not applicableLooking for participantsNCT05650619
What this trial is testing

Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change Disease

Who this might be right for
Focal Segmental GlomerulosclerosisMinimal Change DiseaseFSGS+1 more
University of Michigan 300
Testing effectiveness (Phase 2)Looking for participantsNCT06500702
What this trial is testing

Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease

Who this might be right for
Focal Segmental GlomerulosclerosisGlomerulonephritis Minimal Lesion
Sanofi 84
Not applicableEnded earlyNCT04235621
What this trial is testing

Understand the Genetics and Clinical Course of Focal Segmental Glomerulosclerosis (FSGS), Treatment-Resistant Minimal Change Disease (TR-MCD), and Diabetic Nephropathy (DN)

Who this might be right for
Glomerulosclerosis, Focal SegmentalMinimal Change DiseaseDiabetic Nephropathies
Goldfinch Bio, Inc. 20
Testing effectiveness (Phase 2)Looking for participantsNCT05003986
What this trial is testing

Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases

Who this might be right for
Focal Segmental GlomerulosclerosisMinimal Change DiseaseImmunoglobulin A Nephropathy+2 more
Travere Therapeutics, Inc. 67
Large-scale testing (Phase 3)Study completedNCT00065611
What this trial is testing

Steroid Treatment for Kidney Disease

Who this might be right for
NephrosisFocal Lipoid Glomerulosclerosis
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 8